drugset / Trial / NCT04492787

Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT04492787 ↗

Phase 2 Completed 240 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.

Timeline

Start
2020-07-06
Primary completion
2022-04-21
Completion
2022-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Changkang Granule Unknown — —